Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment

NCT ID: NCT06995846

Last Updated: 2025-05-30

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 700 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-04-02
• Study Completion Date: 2026-06-30

Brief Summary

Background and Significance:

Spontaneous bacterial peritonitis (SBP) is a common and life-threatening complication in patients with liver cirrhosis, characterized by high incidence and mortality. The current diagnostic standard relies on ascitic fluid polymorphonuclear leukocyte (PMN) count ≥250 cells/μL. However, this threshold is associated with high rates of missed diagnoses, poor correlation with clinical symptoms, and delays in pathogen identification due to the low sensitivity and prolonged time of traditional ascitic fluid culture.

With the development of molecular diagnostics, bacterial DNA (bactDNA) detection-especially through droplet digital PCR (ddPCR)-has emerged as a promising technique due to its high sensitivity, absolute quantification capability, and robustness. This study aims to evaluate the diagnostic value and accuracy of ddPCR-based quantification of bacterial DNA in ascitic fluid for SBP, providing a novel and objective diagnostic tool to improve early and accurate detection and to inform targeted antimicrobial therapy.

Objectives:

To assess the diagnostic accuracy (sensitivity, specificity, predictive values) of ddPCR-based quantification of total bacterial DNA in ascitic fluid for SBP.

To evaluate the diagnostic performance of the ratio of Gram-positive to Gram-negative bacterial DNA (G+/G-) in predicting SBP.

To explore the potential of ddPCR-based bacterial DNA quantification as a complementary or alternative method to conventional PMN-based diagnostic criteria.

Study Design and Methods:

This is a prospective diagnostic study involving 700 patients with liver cirrhosis and ascites. Ascitic fluid samples will be analyzed using ddPCR to quantify bacterial DNA levels. These results will be compared with traditional diagnostic criteria, including PMN counts and expert panel assessments based on clinical symptoms and laboratory findings. Statistical analyses will include correlation analysis, ROC curve analysis, and consistency testing.

Expected Outcomes:

The study aims to establish the clinical efficacy of ddPCR-based quantification of bacterial DNA in ascitic fluid as a novel diagnostic marker for SBP. This method is expected to be particularly useful in atypical cases where PMN counts are <250/μL and may help guide preliminary antibiotic selection based on the proportion of Gram-positive and Gram-negative bacteria, thereby reducing empirical treatment failures and antibiotic resistance.

Conditions

Cirrhosis; Ascites; Bacterial Infections

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Cirrhotic Patients with Ascites

Cirrhotic Patients with Ascites

Bacterial DNA Levels in Ascites

Intervention Type: DIAGNOSTIC_TEST

The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).

Interventions

Bacterial DNA Levels in Ascites

The bactDNA was detected by droplet digital polymerase chain reaction (ddPCR).

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years, no restriction on gender.
• Diagnosis of liver cirrhosis based on imaging, biochemical, or hematological evidence of impaired hepatic synthetic function or portal hypertension, or histologically confirmed cirrhosis, regardless of etiology.
• Diagnosis of ascites according to the 2023 Chinese Clinical Guidelines for the Diagnosis and Treatment of Cirrhotic Ascites and Related Complications.

Exclusion Criteria

• Patients with confirmed infections in other tissues or organs.
• Ascites caused by non-hepatic etiologies, such as renal or cardiac ascites.
• Pregnant individuals, intravenous drug users, or HIV-infected individuals.
• Patients with uncontrolled hepatocellular carcinoma or other systemic malignancies.
• Patients who have previously undergone organ transplantation.
• Patients currently receiving glucocorticoids or other immunosuppressive therapies.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing YouAn Hospital

OTHER

Sponsor Role: lead

Responsible Party

Zhongjie Hu

associate dean

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

No. 8 You An Men Wai Street, Fengtai District, Beijing 100069, China

Beijing, , China

Countries

China

Other Identifiers

LL-2024-034-K

Identifier Type: -

Identifier Source: org_study_id